San Francisco, CA, United States of America

Jocelyn Chan


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jocelyn Chan in the Field of Biotechnology

Introduction

Jocelyn Chan is a notable inventor based in San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the area of cancer research. Her work focuses on the modulation of proteins involved in critical signaling pathways.

Latest Patents

Jocelyn Chan holds a patent titled "Human RRP sequences and methods of use." This patent involves Rhomboid Related Proteins (RRPs), which play a crucial role in the EGFR signaling pathway. The patent describes transgenic, nonhuman mammals that contain a transgene encoding an RRP polypeptide. It also outlines methods for modulating the interaction of RRP proteins with their pathway members. Additionally, the patent includes methods for screening agents that can modulate the interaction of RRP polypeptides with RRP binding targets, such as RRP-specific antibodies and small molecules identified through high throughput screens. The modulating agents identified using these methods can be utilized to specifically inhibit the growth of tumor cells that overexpress RRP proteins.

Career Highlights

Jocelyn Chan is currently employed at Exelixis, Inc., where she continues her research and development efforts. Her work at Exelixis focuses on innovative solutions for cancer treatment and drug discovery.

Collaborations

Some of her notable coworkers include Mario N Lioubin and Lori Friedman, who contribute to the collaborative environment at Exelixis, Inc.

Conclusion

Jocelyn Chan's innovative work in biotechnology, particularly her patent on RRP sequences, showcases her commitment to advancing cancer research. Her contributions are vital in the ongoing fight against cancer and highlight the importance of collaboration in scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…